CatalystFDA/Bio

REGENERON PHARMACEUTICALS (REGN) ADJUSTS COURSE AMID MIXED RESULTS IN MELANOMA DRUG TRIALS - YAHOO

Mixed melanoma trial results create uncertainty, driving high investor attention.

What changed

Mixed melanoma trial results create uncertainty, driving high investor attention.

Why it matters

Mixed melanoma trial results create uncertainty, driving high investor attention. — impact context not separately stored; see What changed.

Sources